Modafinil

Generic Name
Modafinil
Brand Names
Provigil
Drug Type
Small Molecule
Chemical Formula
C15H15NO2S
CAS Number
68693-11-8
Unique Ingredient Identifier
R3UK8X3U3D
Background

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...

Indication

To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
Associated Therapies
-

Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-22
Last Posted Date
2019-04-10
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
123
Registration Number
NCT00218387
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Medical University of South Carolina, Charleston, South Carolina, United States

Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

First Posted Date
2005-09-22
Last Posted Date
2012-07-26
Lead Sponsor
Cephalon
Registration Number
NCT00214981
Locations
๐Ÿ‡บ๐Ÿ‡ธ

UCI Child Development Center, Irvine, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Marshfield Clinical Research, Marshfield, Wisconsin, United States

๐Ÿ‡บ๐Ÿ‡ธ

Kentucky Pediatric/Adult Resea, Bardstown, Kentucky, United States

and more 52 locations

Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-09-22
Last Posted Date
2012-05-31
Lead Sponsor
Cephalon
Target Recruit Count
92
Registration Number
NCT00214968

Modafinil for Atypical Depression

Phase 2
Completed
Conditions
First Posted Date
2005-09-22
Last Posted Date
2013-06-19
Lead Sponsor
Duke University
Target Recruit Count
65
Registration Number
NCT00215176

Medications for Stopping Cocaine Dependence and Preventing Relapse

First Posted Date
2005-09-22
Last Posted Date
2017-06-09
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
101
Registration Number
NCT00218023
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The University of Texas Health Science Center at Houston, Houston, Texas, United States

Fatigue Treatment Using Provigil

Not Applicable
Conditions
First Posted Date
2005-09-22
Last Posted Date
2006-02-17
Lead Sponsor
Sheba Medical Center
Target Recruit Count
50
Registration Number
NCT00220506
Locations
๐Ÿ‡ฎ๐Ÿ‡ฑ

Multiple Sclerosis Center, Tel Hashomer, Israel

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

Phase 4
Completed
Conditions
First Posted Date
2005-09-21
Last Posted Date
2013-11-11
Lead Sponsor
Emory University
Target Recruit Count
100
Registration Number
NCT00208715
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Emory University, Atlanta, Georgia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Stanford University, Stanford, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mount Sinai School of Medicine, New York, New York, United States

and more 1 locations

Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-15
Last Posted Date
2015-12-23
Lead Sponsor
University of Rochester
Target Recruit Count
96
Registration Number
NCT00178373
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States

Provigil (Modafinil) Study by Taiwan Biotech Co.

First Posted Date
2005-09-15
Last Posted Date
2005-09-15
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
30
Registration Number
NCT00174174
ยฉ Copyright 2024. All Rights Reserved by MedPath